November 27, 2009 (FinancialWire) — Derma Sciences, Inc. (OTCBB: DSCI) said that its shareholders have granted Derma Sciences’ board authority to implement a reverse stock split in the range of between one-to-five and one-to-10.

Company CEO Ed Quilty said, “We have filed an application to list our stock on the NASDAQ Global Market or NASDAQ Capital Market. The reverse stock split our stockholders approved at TODAY’s special meeting will enable Derma Sciences to meet the minimum share-price requirements of the NASDAQ listing.”

New Jersey-based Derma Sciences is a specialty medical device and pharmaceutical company focusing on advanced wound care.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.